TENX

Tenax Therapeutics, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.93
52-Week Range: $1.31 – $19.40
Market Cap: $74.10M
P/E (TTM): —
EPS (TTM): -1.48
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.90
PEG Ratio: 1.44
Return on Equity: -59.80%
Return on Assets: -37.70%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 15.07
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-24.05M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-4.56M

TENX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$5.38M	$3.23M	$12.71M	$32.67M
Selling, General & Admin	$5.68M	$5.00M	$6.79M	$23.71M
Operating Expenses	$11.05M	$8.23M	$19.49M	$56.38M
Operating Income	-$11.05M	-$8.23M	-$19.49M	-$56.38M
EBITDA	-$10.93M	-$7.68M	-$17.58M	-$52.60M
Pretax Income	-$11.05M	-$7.71M	-$17.60M	-$52.60M
Net Income	-$11.05M	-$7.71M	-$17.60M	-$52.60M
Diluted EPS	-600.71	-31.04	-1.15	-1.34
Diluted Shares	18391	248447	15.27M	39.22M

TENX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$2.12M	$9.79M	$94.85M	$97.56M
Current Assets	$3.21M	$11.68M	$96.69M	$104.23M
Total Assets	$3.40M	$11.69M	$96.69M	$104.23M
Current Liabilities	$1.85M	$3.59M	$4.69M	$7.16M
Total Debt	$807.89K	$501.00K	—	—
Total Liabilities	$1.91M	$3.59M	$4.69M	$7.16M
Retained Earnings	-$289.54M	-$297.25M	-$314.86M	-$367.45M
Shareholders' Equity	$1.49M	$8.10M	$91.99M	$97.07M
Working Capital	$1.36M	$8.10M	$91.99M	$97.07M

TENX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$11.39M	-$5.90M	-$14.81M	-$35.80M
Capital Expenditure	-$2.32K	—	—	—
Free Cash Flow	-$11.39M	-$5.90M	-$14.81M	-$35.80M
Depreciation & Amortisation	$113.33K	$8.00K	$0.00	—
Stock-Based Compensation	—	$191.00K	$1.13M	$19.16M
Investing Cash Flow	-$2.32K	$3.00K	$0.00	—
Financing Cash Flow	$7.93M	$13.57M	$99.87M	$38.51M
Net Change in Cash	-$3.46M	$7.67M	$85.06M	$2.71M

TENX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$5.68M	$6.12M	$10.33M	$10.54M	$11.54M	$12.85M
Selling, General & Admin	$5.66M	$5.67M	$6.48M	$5.91M	$5.03M	$5.93M
Operating Expenses	$11.34M	$11.79M	$16.81M	$16.45M	$16.57M	$18.78M
Operating Income	-$11.34M	-$11.79M	-$16.81M	-$16.45M	-$16.57M	-$18.78M
EBITDA	-$11.34M	-$11.79M	-$15.80M	-$15.54M	-$16.57M	-$18.78M
Pretax Income	-$10.41M	-$10.85M	-$15.80M	-$15.54M	-$15.72M	-$17.80M
Net Income	-$10.41M	-$10.85M	-$15.80M	-$15.54M	-$15.72M	-$17.80M
Diluted EPS	-0.28	-0.27	-0.40	—	-0.35	-0.35
Diluted Shares	36.58M	39.57M	39.74M	—	45.23M	50.87M

TENX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$111.45M	$105.46M	$99.37M	$97.56M	$118.75M	$117.98M
Current Assets	$112.06M	$105.86M	$102.81M	$104.23M	$123.18M	$121.66M
Total Assets	$112.06M	$105.86M	$102.81M	$104.23M	$123.18M	$121.66M
Current Liabilities	$2.77M	$2.53M	$6.60M	$7.16M	$8.49M	$8.07M
Total Liabilities	$2.77M	$2.53M	$6.60M	$7.16M	$8.49M	$8.07M
Retained Earnings	-$325.26M	-$336.11M	-$351.91M	-$367.45M	-$383.17M	-$400.97M
Shareholders' Equity	$109.29M	$103.33M	$96.21M	$97.07M	$114.69M	$113.59M
Working Capital	$109.29M	$103.33M	$96.21M	$97.07M	$114.69M	$113.59M

TENX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$6.97M	-$6.26M	-$9.15M	-$13.41M	-$9.31M	-$14.15M
Free Cash Flow	-$6.97M	-$6.26M	-$9.15M	-$13.41M	-$9.31M	-$14.15M
Stock-Based Compensation	$4.14M	$4.61M	$5.62M	$4.79M	$2.84M	$3.33M
Investing Cash Flow	$0.00	$0.00	$0.00	—	—	—
Financing Cash Flow	$23.56M	$278.00K	$3.06M	$11.61M	$30.50M	$13.37M
Net Change in Cash	$16.60M	-$5.99M	-$6.09M	-$1.80M	$21.19M	-$779.00K

Market Snapshot

About

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market. The company is developing levosimendan, a calcium sensitizer, for the treatment of pulmonary hypertension associated with heart failure. Tenax aims to address unmet medical needs in cardiovascular and pulmonary diseases.